---
title: "Invivyd Inc. Launches New Discovery Program for Monoclonal Antibody Treatment Targeting Measles Infections"
description: "Invivyd Inc. has launched a new discovery program aimed at developing a monoclonal antibody treatment for measles infections. This initiative responds to healthcare providers' requests for therapeutic"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239823095.md"
published_at: "2025-05-12T11:06:12.000Z"
---

# Invivyd Inc. Launches New Discovery Program for Monoclonal Antibody Treatment Targeting Measles Infections

> Invivyd Inc. has launched a new discovery program aimed at developing a monoclonal antibody treatment for measles infections. This initiative responds to healthcare providers' requests for therapeutic options due to declining vaccination rates, with over 20 million Americans unvaccinated. The program seeks to identify a preclinical candidate by 2025, with updates expected by year-end. This effort is part of Invivyd's broader research into monoclonal antibodies for COVID-19, RSV, and influenza.

Invivyd Inc. has announced the initiation of a new discovery program focused on developing a monoclonal antibody treatment for measles. This effort comes in response to requests from multiple healthcare providers seeking a therapeutic option for active measles infections and post-exposure prophylaxis amid declining vaccination rates. With over 20 million Americans unvaccinated against measles, this program aims to expedite the path towards the functional eradication of the virus. Invivyd plans to identify a preclinical measles monoclonal antibody candidate by 2025, with a progress update expected by the end of the year. This initiative complements Invivyd's ongoing discovery programs for next-generation COVID-19, RSV, and influenza monoclonal antibodies.

### Related Stocks

- [IVVD.US - Invivyd](https://longbridge.com/en/quote/IVVD.US.md)
- [WBD.US - Warner Bros. Discovery](https://longbridge.com/en/quote/WBD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Invivyd｜8-K：2025 财年 Q4 营收 17.2 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/271929653.md) |
| Invivyd 报告初步的第四季度收入并启动第三阶段 DECLARATION 试验 | Invivyd Inc. 报告了 2025 年第四季度的初步结果，PEMGARDA®的净产品收入为 1720 万美元，同比增长 25%。公司在年末拥有 2.267 亿美元的现金，之前筹集了超过 2 亿美元的融资。Invivyd 启动了 VY | [Link](https://longbridge.com/en/news/271928371.md) |
| Invivyd 的 COVID 抗体 VYD2311 获得美国食品药品监督管理局（FDA）的快速通道资格 | Invivyd 宣布，FDA 已授予其 COVID 抗体 VYD2311 快速通道认证，旨在预防高风险人群中的 COVID。这一认证可能会加快监管审查，预计 2026 年中期将公布 3 期试验结果。Invivyd 希望加强其在 COVID  | [Link](https://longbridge.com/en/news/270616066.md) |
| Invivyd, Inc. (IVVD)：尽管分析师下调评级，仍在推进 RSV 抗体 VBY329 的研发 | Invivyd Inc.（纳斯达克代码：IVVD）已选择 VBY329 作为预防新生儿、婴儿和儿童呼吸道合胞病毒（RSV）的单克隆抗体候选药物。该决定于 11 月 24 日做出，利用了公司的专有抗体发现技术。尽管分析师下调了评级，但 Inv | [Link](https://longbridge.com/en/news/270127084.md) |
| BUZZ-Invivyd 因在后期试验中测试 COVID 抗体对 mRNA 疫苗的效果而股价上涨 | Invivyd 的股票在盘前交易中上涨 5.17%，至 1.83 美元，此前该公司宣布启动其 COVID 抗体 VYD2311 的晚期试验，该试验将与 mRNA 疫苗进行对比测试。该研究旨在招募约 210 名参与者，以比较安全性，并将探讨抗 | [Link](https://longbridge.com/en/news/274653017.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.